EUVIMEDEUVIMED entdecken
Crossref

Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression

Luis E Aguirre, Somedeb Ball, Akriti Jain, Najla Al Ali, David A Sallman, Andrew Kuykendall, Kendra Sweet, Jeffrey E Lancet, Eric Padron, Rami S Komrokji

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.03.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Luis E Aguirre und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Harvard T.H. Chan School of P…. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder characterized by features of myeloproliferation and myelodysplasia. Various prognostic models incorporate clinical, cytogenetic, and molecular factors to assess risk and guide treatment decisions. However, there has been limited exploration of a subset of patients exhibiting more indolent disease behavior. Due to the significant heterogeneity in disease biology, clonal architecture, clinical presentation, and outcomes, identifying key markers is essential for predicting which patients may present with indolent disease and for recognizing those at greater risk of progression who may require early intervention. PATIENTS AND METHODS: We analyzed baseline clinical and molecular parameters in 656 CMML patients, stratifying them into 2 groups: those observed for ≥ 3 years (indolent CMML) and those needing treatment within that period. RESULTS: 14% of CMML patients exhibited indolent disease, correlating with superior outcomes (mOS: 78.5 months vs. 25 months in nonindolent cases). Indolent disease was associated with higher hemoglobin and platelet counts, JAK2 mutations, and fewer cytopenias. In contrast, features indicating the need for earlier treatment included leukocytosis, elevated lymphocyte/monocyte counts, higher percentage of circulating immature cells/blasts, increased marrow cellularity/blasts, and NRAS, ASXL1, and RUNX1 mutations. Changes in the M:E ratio, the presence of abnormally localized immature precursors (ALIP) and gain of mutations reflecting clonal evolution indicated clinical decline and need for timely treatment initiation. CONCLUSION: A small proportion of CMML patients exhibit indolent features linked to better outcomes, contrasting with markers indicating earlier treatment initiation, which are associated with increased risk of progression; recognizing these markers aids in predicting disease aggressiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, ChronicHumansDisease ProgressionMaleFemaleAgedPhenotypeMiddle AgedAged, 80 and overPrognosisAdultMutation

Stichwörter der Autor:innen

Chronic myelomonocytic leukemia (CMML)Clonal evolutionIndolent CMMLMDS/MPNMyelodysplastic syndromes

Autor:innen und Institutionen

  • Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA. Electronic address: luis_aguirre@dfci.harvar…
  • Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN.
  • Taussig Cancer Institute, Leukemia and Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address: rami.komrokji@moffitt.org.

Zitieren

APA

Aguirre, L. E., Ball, S., Jain, A., Ali, N. A., Sallman, D. A., Kuykendall, A., Sweet, K., Lancet, J. E., Padron, E., & Komrokji, R. S. (2025). Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.03.016

Vancouver

Aguirre LE, Ball S, Jain A, Ali NA, Sallman DA, Kuykendall A, et al. Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.03.016

BibTeX
@article{Aguirre2025,
  author = {Aguirre, Luis E and Ball, Somedeb and Jain, Akriti and Ali, Najla Al and Sallman, David A and Kuykendall, Andrew and Sweet, Kendra and Lancet, Jeffrey E and Padron, Eric and Komrokji, Rami S},
  title = {Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.03.016}
}
Kostenlos starten →